Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Son, Seok H ^a   Jang, Hong S ^b   Jo, In Young ^a   Choi, Byung O ^b   Jang, Jeong W ^a   Yoon, Seung K ^b   Kay, Chul S ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

An increase in Child Pugh score; Radiotherapy; Unresectable hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; DUODENUM; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; KIDNEY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PATIENT SELECTION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOFREQUENCY ABLATION; SMALL INTESTINE; SPINAL CORD; STOMACH; SURVIVAL TIME; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COMPUTER ASSISTED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; YOUNG ADULT;

EID: 84900013192     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-101     Document Type: Article

References (24)

1. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224(1):47-54.
2. Lencioni R, Pinto F, Armillotta N, Bassi AM, Moretti M, Di Giulio M, Marchi S, Uliana M, Della Capanna S, Lencioni M, Bartolozzi C. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997, 7(4):514-519.
3. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001, 221(1):159-166.
4. Cochrane AM, Murray-Lyon IM, Brinkley DM, Williams R. Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer 1977, 40(2):609-614.
5. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995, 31(5):1237-1248.
6. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, Yoo BC, Lee JE, Kang MK, Park YJ, Nam HR, Ahn YC, Huh SJ. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005, 61(4):1143-1150.
7. Cheng JC, Chuang VP, Cheng SH, Huang AT, Lin YM, Cheng TI, Yang PS, You DL, Jian JJ, Tsai SY, Sung JL, Horng CF. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000, 47(2):435-442.
8. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO, Kim GE. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999, 43(2):393-397.
9. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56(4):918-928.
10. Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB, Lee WJ, Park SJ, Hong EK, Kim CM. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67(1):225-231.
11. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53(4):810-821.
12. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006, 65(2):426-434.
13. Liang S, Huang X, Zhu X, Zhang W, Cai L, Huang H, Li Y, Chen L, Liu M. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh Grade A cirrhosis. Radiother Oncol 2011, 98(2):265-269.
14. Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, Yoon SK, Choi IB, Kang KM, Jang HS. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 2010, 78(4):1073-1080.
15. Lee IJ, Seong J, Shim SJ, Han KH. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys 2009, 73(1):154-158.
16. Cheng JC, Wu JK, Huang CM, Liu HS, Huang DY, Cheng SH, Tsai SY, Jian JJ, Lin YM, Cheng TI, Horng CF, Huang AT. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002, 54(1):156-162.
17. Cheng J, Wu J, Lee P, Liu H, Jian J, Lin Y, Sung J, Jan G. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004, 60:1502-1509.
18. Dawson LA, Biersack M, Lockwood G, Eisbruch A, Lawrence TS, Ten Haken RK. Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys 2005, 62(3):829-837.
19. Son SH, Kay CS, Song JH, Lee SW, Choi BO, Kang YN, Jang JW, Yoon SK, Jang HS. Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma. Radiat Oncol 2013, 8:11. 3552734, 23298438.
20. Furuse J, Ishii H, Nagase M, Kawashima M, Ogino T, Yoshino M. Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2005, 20(10):1512-1518.
21. Liaw Y, Sung JJ, Chow WC, Farrell G, Lee C, Yuen H, Tanwandee T, Tao Q, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, . Cirrhosis Asian Lamivudine Multicentre Study Group Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351(15):1521-1531. Cirrhosis Asian Lamivudine Multicentre Study Group.
22. Ogata K, Hizawa K, Yoshida M, Kitamuro T, Akagi G, Kagawa K, Fukuda F. Hepatic injury following irradiation-a morphologic study. Tokushima J Exp Med 1963, 43:240-251.
23. Yoon SM, Lim Y, Won HJ, Kim JH, Kim KM, Lee HC, Chung Y, Lee YS, Lee SG, Park JH, Suh DJ. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012, 82(5):2004-2011.
24. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. Radiat Oncol 2010, 10:475.